Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 277

1.

Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists.

Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, Goenka N, Thomas EL, Adams VL, Pushpakom SP, Pirmohamed M, Kemp GJ.

PLoS One. 2012;7(12):e50117. doi: 10.1371/journal.pone.0050117. Epub 2012 Dec 6.

2.

Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.

Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M.

Obesity (Silver Spring). 2011 Dec;19(12):2310-5. doi: 10.1038/oby.2011.152. Epub 2011 Jun 9.

3.

Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.

Vergès B, Bonnard C, Renard E.

Diabetes Metab. 2011 Dec;37(6):477-88. doi: 10.1016/j.diabet.2011.07.001. Epub 2011 Aug 25. Review.

PMID:
21871831
4.

Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.

Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D, Zinman B.

Diabetes Obes Metab. 2013 Jan;15(1):42-54. doi: 10.1111/j.1463-1326.2012.01673.x. Epub 2012 Sep 9.

PMID:
22862847
5.

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.

Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, Düring M, Zdravkovic M, Strauss BJ, Garber AJ; LEAD-2 and LEAD-3 Study Groups.

Diabetes Obes Metab. 2009 Dec;11(12):1163-72. doi: 10.1111/j.1463-1326.2009.01158.x.

PMID:
19930006
6.

Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.

Hayes MR, Kanoski SE, Alhadeff AL, Grill HJ.

Obesity (Silver Spring). 2011 Jul;19(7):1342-9. doi: 10.1038/oby.2011.50. Epub 2011 Mar 17.

7.

The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.

de Boer SA, Lefrandt JD, Petersen JF, Boersma HH, Mulder DJ, Hoogenberg K.

Int J Clin Pharm. 2016 Feb;38(1):144-51. doi: 10.1007/s11096-015-0219-8. Epub 2015 Nov 23.

8.

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.

Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, Ni Y, Liu D, Zhu Z.

Diabetes Obes Metab. 2013 Aug;15(8):737-49. doi: 10.1111/dom.12085. Epub 2013 Mar 20.

PMID:
23433305
9.

Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.

Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A, Okita K, Imagawa A, Funahashi T, Shimomura I.

Cardiovasc Diabetol. 2011 Dec 1;10:109. doi: 10.1186/1475-2840-10-109.

14.

Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy.

Dutour A, Abdesselam I, Ancel P, Kober F, Mrad G, Darmon P, Ronsin O, Pradel V, Lesavre N, Martin JC, Jacquier A, Lefur Y, Bernard M, Gaborit B.

Diabetes Obes Metab. 2016 Sep;18(9):882-91. doi: 10.1111/dom.12680. Epub 2016 May 31.

PMID:
27106272
15.

Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide*.

Paul S, Best J, Klein K, Han J, Maggs D.

Diabetes Obes Metab. 2012 Sep;14(9):826-34. doi: 10.1111/j.1463-1326.2012.01609.x. Epub 2012 May 16.

PMID:
22510305
16.

The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.

Morales J.

Postgrad Med. 2011 Nov;123(6):189-201. doi: 10.3810/pgm.2011.11.2508. Erratum in: Postgrad Med. 2012 Jan;124(1):177-8.

PMID:
22104467
17.

GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.

Esposito K, Mosca C, Brancario C, Chiodini P, Ceriello A, Giugliano D.

Curr Med Res Opin. 2011 Aug;27(8):1519-28. doi: 10.1185/03007995.2011.590127. Epub 2011 Jun 13.

PMID:
21663496
18.

Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes.

Forti A, Garcia EG, Yu MB, Jimenez MC, Brodows RG, Oliveira JH.

Curr Med Res Opin. 2008 Sep;24(9):2437-47. doi: 10.1185/03007990802282398 . Epub 2008 Jul 24.

PMID:
18662495
19.
20.

Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.

Blonde L, Montanya E.

Diabetes Obes Metab. 2012 Apr;14 Suppl 2:20-32. doi: 10.1111/j.1463-1326.2012.01575.x. Review.

PMID:
22405266

Supplemental Content

Support Center